Trial Profile
An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, eg. Parkinson's disease, Huntington's disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2020
Price :
$35
*
At a glance
- Drugs OSU 6162 (Primary)
- Indications Chronic fatigue syndrome
- Focus Adverse reactions
- 05 Dec 2020 Status changed from recruiting to completed.
- 15 Jul 2014 New trial record